



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

WILLIAMS *et al.*

Appl. No. 09/839,946

Filed: April 19, 2001

For: **PEG-Urate Oxidase Conjugates  
and Use Thereof**

Confirmation No. 5256

Art Unit: 1652

Examiner: Saidha, T.

Atty. Docket: 2057.0090003/JAG/BJD

**Fourth Supplemental Information Disclosure Statement**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on December 11, 2003, in connection with the above-captioned application. A copy of each document is also provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Fourth Supplemental Information Disclosure Statement is being filed before the mailing of a final action on the merits or a Notice of Allowance, but after the mailing of a first action on the merits, in the captioned application. In accordance with 37 C.F.R. § 1.97(c), fee payment under 37 C.F.R. § 1.17(p) is provided herewith.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono  
Attorney for Applicants  
Registration No. 42,473

Date: Dec. 16, 2003

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

**FOURTH SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT**ATTY. DOCKET NO.  
2057.0090003/JAG/BJDAPPLICATION NO.  
09/839,946APPLICANT  
Williams et al.FILING DATE  
April 19, 2001GROUP  
1652**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AR	20	Alvares, K., et al., "The nucleotide sequence of a full length cDNA clone encoding rat liver urate oxidase," <i>Biochem. Biophys. Res. Commun.</i> 158:991-995 (1989).
	AS		
	AT		

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



**COPY**

**Applicant:** Williams *et al.*

**Due Date:** n/a

**Art Unit:** 1652

**Examiner:** Saidha, T.

**Application No.:** 09/839,946

**Docket:** 2057.0090003

**Filed:** April 19, 2001

**Atty:** JAG/BJD

**For:** PEG-Urate Oxidase Conjugates and Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Credit Card Payment Form (PTO-2038) in the amount of \$130.00 to cover the appropriate fees;
3. PTO Fee Transmittal (PTO/SB/17);
4. Fourth Supplemental Information Disclosure Statement;
5. One page of Form PTO-1449 citing one document;
6. A copy of the cited document (AR20); and
7. One (1) return postcard.



Please Date Stamp And Return To Our Courier

::ODMA\MHODMA\SKGF\_DC1;210377;1